Trust me, trust no one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah the bullshit statements against FUNN continue to grow thats for sure. If even one tenth of the negative criticisms were true the company wouldnt have survived the pandemic. But here they are thriving. They would have gone bankrupt but they are no where near doing that. They would be delisted but against more total bs lobbied against the company.
Snakes and Lattes will be around for decades as the mission of Locations coast to coast becomes a reality
$FUNN
Six Quarters in a row going up and continues to go up Q over Q since the pandemic. Going to be seven. Revenues in the millions and not slowing down. Thriving and stronger.
Market strength, momentum and will continue to grow locations, customers and revenues.
Sounds like that statement is really what is bs.
$FUNN
What if there was a topical cream that treated #PTSD without side effects? Don't miss our latest feature in @Benzinga - exploring the exciting possibilities of Psycheceutical's NeuroDirect™ Ketamine for treating PTSD. https://t.co/HvXGgW54eg
— Psycheceutical (@psycheceutical) March 28, 2023
We have consistently seen random predictions and misinformation on the company posted for years. Like you said. Not even close.
Company is stronger than ever and the basis for growth and opportunity is stronger than ever. The brand continues to grow and our network and connections in the industry becomes more powerful by the day.
Snakes & Lattes coming coast to coast in North America. This latest West Beach Virginia location is awesome and we will keep on opening new locations.
We are really starting to thrive. Millions in revenues increasing Q after Q going on 7 quarters in a row now.
$FUNN
Friday folks will line up at our Snakes and Lattes, enjoying food game and drink. Having a great time and driving our 7th Q in a row of increasing revenues in the millions. Facts. Company and brand stronger than ever.
Looking forward to the next update
$FUNN
The time is now.
— Zappy Zapolin (@ZappyZapolin) March 24, 2023
Peace. Zappy
Via @TheDalesReport:
Is the rising positive data points of psychedelic research for mental health treatments enough reason for investors to jump now in the space? Is this the sign that the industry is worth diving?https://t.co/PODZ7bvGCJ pic.twitter.com/pjh5uk7cUL
Exactly, face forward and remain grounded in reality. The company and future is stronger than ever. Love the prospects here. If i have a question i pick up the phone and call the CEO.
Looking forward to the next update and a 7th quarter of revenue growth!
Wow that statement is a load of poo. There is no smoke in the lines out the door at the packed Tempe location. There are no mirror about the new Virginia Beach location. Nothing hazy on the fact we have had 6 quarters of increasing revenue growth in the millions with the latest being net profitable. The brand strength increases a 7th Q of growth is happening and just keeps getting better. Thousands of customers each and every single week and millions in revs that is growing along with locations. Its the opposite of ‘a rut’ Its solid growth
$FUNN
CAH certainly did create a 7 mil anomaly back then. Fortunately, the company is much stronger now and continues to thrive. Its an incredibly good deal at this range. We have so many things in our favor now. The continue trending revenue. Growth is great marching towards for annual profitability continuing to add great locations, the branch strength continues to rise. Looking forward to the growing and optimistic future. So some folks may be down, but we’ve got momentum back and are doing well in the future looks much nicer. There are certainly worse scenarios in the OTC to be in a we still have a very strong company.
Take a look at some exciting pre-clinical observational data published in the latest issue of Drug Development & Delivery that supports the potential of our NeuroDirect™ ketamine topical cream as a treatment for #PTSD. $BWVI
— Psycheceutical (@psycheceutical) March 22, 2023
Read the news: https://t.co/jWr1ik8i9P pic.twitter.com/tiGHTEpVw3
The following is a testimonial from a patient who used NeuroDirect ketamine: “It was like truth serum! I became aware of thoughts and emotions I had suppressed which needed to come out. I found myself crying uncontrollably as I released them. It allowed me to move forward as I had been stuck in a rut. I began to feel so much better as I faced how selfishly and un-lovingly I had treated my ill mother before she suddenly passed away.” Another stated “The usual triggers no longer affected me to go into a panic state…”
Amazing news! This company is on the way to greatness!
That exists in most otcs, for us there is a wall between .03 - .05. There will be some churn for a bit there but as the company grows and the value far exceeds the pps it will get overcome and a new floor established. We got another fully funded location coming and we get that we are easily hitting $10 M a year and decent chance at annual level profitability. Get that and so many new channels open up.
Looking great! Good reasons to be optimistic after a tough couple of years.
$FUNN
Between that and the giant mall it is next too, it is an amazing location! Snakes & Lattes will optimize the location and the brand will continue to strengthen.
$FUNN
In a new White House report on mental health research priorities, the Oval Office calls for increased focus on identifying, supporting, treating and researching solutions to the nation's mental health crisis.
— Psycheceutical (@psycheceutical) March 20, 2023
Read the report: https://t.co/526zdW6RP0 pic.twitter.com/mfMfAKgJlo
Yup, great spot! Lots of room for more seating as well. They are going to need it!
We just keep on growing revenues, customers, metrics trending in the right direction.
Thriving again!
$FUNN
Exactly, bs cries of going away etc just pure bs. We survived and now thriving just like I said we would long term. Its just going to keep getting stronger. More revs in millions, thousands of customers weekly and growing to tens of thousands. Locations across North America and better optimization and efficiency equaling better margins.
Looking great!
$FUNN
This isnt franchising at this point. That will require enough US presence that generates US fiscal data. Once that is done then we can engage the US banking system and make huge moves. For now, private friendly placements are the best route. Its great we are getting them!
$FUNN
Nice little hits today it moves up, when the mass
Volume kicks in going to be amazing
Nah, besides there are very few dry locations that will meet requirements. Utah was simply an opportunity. It will never be as big as the larger Snakes locations, but its a nice little revenue generator that adds to the bottom line. It came extremely cheap and was reasons to say yes to it than no.
In general its all Snakes & Lattes, i dont expect many Utah scenarios. But hey, if they do another one off and if it makes money its all good
Yes exactly, there is confidence in the model and business. Getting these types of deals is amazing. The strength of the brand keeps growing and allowing for better deals without dilution
Looking forward to the next update!
$FUNN
Yep, generally default IT WILL be a Snakes & Lattes. Utah is very much an exception.
Future looks GREAT here!
$FUNN
This is awesome! Amazing location, lots of foot traffic, families play games and eat while folks do shopping at the mall. Huge place, and yeah like it says right in the PR, its a Snakes & Lattes!
Really bringing it home now we are on a great march to the Vision. And we know ANOTHER
will be coming, already funded!
It is AWESOME they can do this without dilution as well. Speaks to the brand strength. The model is working as millions come pouring in.
Snakes & Lattes coast to coast is on!
$FUNN
Snakes & Lattes Inc. Acquires a New Brick & Mortar Location in Virginia Beach, Virginia
Press Release | 03/20/2023
TORONTO, ON, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Snakes & Lattes Inc. (OTC: FUNN) is pleased to announce the acquisition of ‘Roll With It’ Board Game Cafe & Bar (Roll With It) in Virginia Beach, Virginia via an all cash transaction.
Acquisition Highlights:
Completed acquisition of ‘Roll With It’ Board Game Café & Bar in Virginia Beach
All cash deal Very popular, Operating Café & Bar with little competition in the area
Strong revenue, well managed, with a similar company culture
Over 4700 sq. ft. in a high-traffic area with lots of visibility and parking.
Marks the first location on the East Coast of the USA (5th USA location To Date)
Established in August 2021 by Quan Truong, ‘Roll With It’ is extremely well managed, has a great company culture, strong revenue and little to no competition in the area. Mr. Truong is assisting the company through the transition.
“I’m really proud of the work that my team and I have done to establish ‘Roll With It’ as a premier entertainment destination for Virginia Beach and the wider Hampton Roads area. When I first started considering a sale in order to have more time for my family, Snakes & Lattes was an obvious choice for taking up the mantle of continuing what we’ve built at ‘Roll With It’. Snakes & Lattes was an inspiration for a lot of the decisions and direction at the company and I’m thrilled to have them take over. I’m excited for the future of ‘Roll With It’ under Snakes & Lattes leadership!” stated Mr. Truong.
The location is expected to stay open during the transition period and the goal of the company is to complete this by summer. Snakes & Lattes Inc. financed the acquisition through non-convertible promissory notes with a 5% interest rate and friendly repayment terms. The notes do not have a convertible feature and no common stock was associated with the financing.
‘Roll With It’ is located in very close proximity to Lynnhaven Mall. This is the largest in the Hampton Roads metropolitan area and one of the largest on the East Coast. ‘Roll With It’ offers entertainment convenience in a high traffic area with plenty of parking and very high visibility.
https://rollwithitbgcafe.com/
Virginia Beach, a city of ~500,000 people is a vibrant coastal city in southeastern Virginia which caters to year-round visitors. The 42nd largest city in the US, the oceanfront destination is rich with history, and home to a variety of arts and entertainment experiences, family-friendly activities, and a blossoming culinary scene. It hosts a lot of tourism, Military and large corporate activity.
Overall, the company is very pleased with the ‘Roll With It’ acquisition as it is an amazing venue and location from all viewpoints. The addition of what will become the new Snakes & Lattes ‘Virginia Beach’ location will provide a strong contribution to the continued expansion of Snakes & Lattes and its ever-increasing brand.
With the first East Coast location and now the 5th overall in the USA, the company continues to be excited about the future as it marches forward on its plan to have Snakes & Lattes locations coast to coast in North America!
Looking ahead, the company continues to advance its strong growth trend. Snakes & Lattes has a number of initiatives underway including additional ongoing discussions for location expansion. Upon successful closing and completion of the next project or any other active initiative, shareholders can expect detailed announcements to follow.
See you at Snakes & Lattes!
About Snakes & Lattes Inc.
Snakes & Lattes Inc. currently operates 8 tabletop gaming bars and cafes: 3 located in Toronto, Ontario, Canada, 1 in Tempe, Arizona, 1 in Tucson, Arizona, 1 in Provo, Utah, 1 in Chicago, Illinois and 1 in Virginia Beach, Virginia. The company is in the process of expanding throughout North America. Snakes & Lattes Inc. was the first board game bar and cafe in North America, and is believed to be the largest in the world. Our board game cafes have the largest circulating public library of board games in North America for customers to choose from.
For more information on Snakes & Lattes Inc., please visit the website at: www.snakesandlattes.com.
For further updates from Snakes & Lattes inc., please follow us on Twitter @SnakesandLattes.
Safe Harbor Statement
This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company's OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should,", "will", "expect," "anticipate," "believe," "estimate," "confident," "intend," "plan", “trending” and other similar expressions. Our actual results, such as the Company's ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Contact:
Ben Castanie
Snakes & Lattes Inc.
Telephone: (646) 992 3348
Email: investors@snakesandlattes.com
Utah there’s an exception due to local religion, being a dry area. That was mentioned in the PR. This one will be Snakes & Lattes. Generally, all of them will be.
And there’s gonna be a lot more!
Great PR!!!! With the addition of that one in the next one, really hitting our stride and profitability!
$FUNN
Nice deep-dive into MDMA-assisted therapy for couples. Not even close to a new concept, but glad to see it in focus here in @TIME!
— Zappy Zapolin (@ZappyZapolin) March 17, 2023
Peace. Zappy https://t.co/dp15lKAcIG
Keith Webb is a genuine, wholesome and caring human being; just a good person. The fact he kept such a super clean share structure and did zero shenanigans over the years allowed for the reverse merger to happen. I wish him all the best in his treasure seeking endeavors. His parting gift to us was to find the reverse merger in to this incredible up and coming paycheceutical company with amazing IP and and amazing management team. Dr. Bailes, yeah top neurosurgeon in the USA is part of the company. Keith didnt make money in the merger even, he only wins when the new company wins. He was loyal to his shareholders through to the end. You would be hard-pressed to find a more caring person who thought about the shareholders in the OTC. Thats the facts.
Looking forward to the next update with Psycheutical.com!
$BWVI (which is also changing once finra gets around to changing it!)
1000s of customers will be pouring into our Snakes & Lattes locations over the next few days and spending thousands of dollars which will equate to millions in revenues over the fiscal year. The revenue numbers just keep going up, 6 Qs in a row now. Add a location or two and looking at financial independence, Add 10 and looking at a newly forming major entertainment chain. Future looks very optimistic going forward.
Celebrate #brainawarenessweek with Psycheceutical CVO, @ZappyZapolin, as he talks with @Benzinga about the exciting vision for NeuroDirect™ Ketamine in treating #PTSD.https://t.co/vi9RmMCnV5#clinicaltrials #mentalhealth #drugdelivery pic.twitter.com/cNa1FDPwDd
— Psycheceutical (@psycheceutical) March 16, 2023
Looking forward to next update. Fact is despite criticism, the company survived the pandemic and is now really beginning to thrive. Millions in revenues continues to go up, 6 quarters in a row. Thousands of customers every week and growing. More locations on the way. Full independence financially is happening over time, hit the first profitable quarter post pandemic and id look to FY24 (we have July to June FY) for annual profitability. Its happening, doesnt matter what is said.
Super excited to present at the @Benzinga Psychedelics Capital Conference on April 13 in Miami on behalf of @psycheceutical. So many incredible things happening in this growing industry. Will you be there? Let’s connect! pic.twitter.com/oWpPfiNPOE
— Kaia Roman (@kaiaroman) March 13, 2023
Treasure
Good action this week, she is wanting to break out! Lets get it finra and start moving!
Weekends are $$$ for Snakes and Lattes! Thousands of customers leading to millions in revenues! Moving towards full annual profitability. Future is looking great here!
Great stuff! Everything is headed in the right direction! This industry will be tens of billions in the long run, and help hundreds of millions in the world.
Yes it would seem talking to the source would be a great path to take there.
FUNN brining in the millions in revs, thousand and thousand of customers. Not stopping only trending up looking great!
Excited for the next update!
Great path! Spelled out nicely, working with the fda for the regulatory path to market.
Solid! Looking forward to the next update!
$BWVI
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD| 02/15/2023
Psycheceutical ??enters into agreement with iNGENu to conduct ?human ?clinical trials of NeuroDirect™ ketamine topical ?in Australia
Phase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect™ ketamine
Phase II trial will study 115 participants with PTSD and look at the effectiveness of NeuroDirect™ ketamine on improving their symptoms
MIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced it has entered into an exclusive agreement with iNGENu Pty Ltd. ("iNGENu"), an Australian-based Contract Research Organization (CRO), to design and conduct two clinical trials to evaluate Psycheceutical’s patented NeuroDirect™ ketamine topical delivery system.
Psycheceutical?? ?is planning to conduct the clinical trials in ??Australia. The first in-human, Phase I clinical trial with iNGENu is studying 20 people, each dosed with a single application of NeuroDirect™ ketamine. This trial is designed to test the “Safety, Tolerability, and Pharmacokinetics of NeuroDirect Ketamine in Healthy Adult Volunteers.”
“We’re thrilled to have partnered with iNGENu as we move our proprietary delivery technology into human clinical trials. iNGENu is an industry-leading, full-service CRO providing end-to-end services for companies like ours developing psychedelic drugs. Together, we’re committed to discovering new psychedelic therapies for mental health disorders and central nervous system diseases,” said Psycheceutical CEO Chad Harman. “We’re eager to engage in this next phase of the development of ????our NeuroDirect™ delivery system, which we’re designing to solve the issues with side effects that most psychedelic drug development companies face, while at the same time developing lifesaving mental health treatments.??”
???The subsequent Phase II clinical trial, also with iNGENu, is targeted to involve 115 participants with PTSD and to analyze the effectiveness of NeuroDirect™ ketamine on improving their symptoms. This trial has been designed to be considered for “pivotal clinical trial” recognition by the FDA, which would then allow the Company to proceed directly to a Phase III clinical trial rather than an additional Phase IIb clinical trial, thereby saving the Company significant cost and time.
“Our team is excited to partner with Psycheceutial for their clinical development needs, and we look forward to working together to design and conduct trials with our partners here in Australia,” said Dr. Sud Agarwal, CEO of iNGENu. “We’re impressed with Psycheceutical’s development of psychedelic delivery technologies which potentially offer safer and more effective dosing for patients.”
By conducting its clinical trials in Australia, Psycheceutical can take advantage of the Australian federal government's Research & Development Tax Incentive Program, which will provide rebates to the Company of up to 43.5 percent on eligible expenditures for research and development conducted in Australia. “This saves us a considerable amount of capital for the research and development of other novel compounds in our drug pipeline," said Chad Harman, Psycheceutical CEO.
NeuroDirect™ for Non-Systemic Delivery
Psycheceutical’s NeuroDirect™ non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds such as hallucinations, nausea, and dizziness. NeuroDirect™ is designed to be administered at home instead of a clinical setting, greatly lowering the cost of care for both insurance companies and patients, increasing access to these life-saving treatments for anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic industry, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
About iNGENu
iNGENu is a globally-focused Contract Research Organization (CRO) working exclusively in the cannabinoid and psychedelic space. The company is a full-service CRO performing clinical trials for US, Canadian, and European sponsors in Australia. iNGENu helps companies access the advantages of conducting clinical trials in Australia, including the ability to perform FDA registration clinical trials prior to opening an IND, access to the lucrative 43.5% research and development rebate from the Australian government on all research expenses, and rapid start-up of clinical trials in under 12 weeks.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, (vii) FDA determinations regarding how that recognize and classify one or more our clinical trials and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as “will,” “may,” “should,” “could,” “intend,” “estimate,” “plan,” “anticipate,” “expect,” “believe,” “potential” or “continue,” or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications
kaia.roman@psycheceutical.com
From @WSJ, find out why Wall Street is taking new interest in #psychedelicmedicine and backing companies who are leading the way in research and clinical trials to discover novel approaches for safe & effective #mentalhealth treatments.
— Psycheceutical (@psycheceutical) February 27, 2023
Read More: https://t.co/3w4l2gCmL8